Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral magnesium for prevention of doxorubicin-induced cardiotoxicity in breast cancer
IRCT20251210068277N1Phase 3Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of magnesium in breast cancer and Cardiotoxicity, sponsored by Tehran University of Medical Sciences. Started Jul 2026; status: recruiting.
02
Drugs
magnesium
03
Conditions
breast cancerCardiotoxicity
Beyond the preview
Go deeper on IRCT20251210068277N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251210068277N1.